D-dimer—An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World

Abstract

D-dimer assessment has several established roles in venous thromboembolism (VTE) and disseminated intravascular coagulation diagnosis, and recently the risk stratification of coronavirus disease 2019 (COVID-19). D-dimer assays are neither standardized nor harmonized, use varying methodologies, and use different reporting units, all resulting in a lack of interchangeability and generalizability of assays. Using large multiyear datasets from an international laboratory quality assurance program, we assessed (1) common D-dimer assays in use worldwide, (2) differences in analytical performance between different methods, and (3) interlaboratory variability between positive samples. External proficiency testing results from laboratories participating in the External Quality Control for Assays and Tests (ECAT) Foundation were analyzed from 2017 to 2023. Annually, between 578 and 690 laboratories participated in the D-dimer sample surveys with response rates ranging from 88 to 97%. The three most common assays in use in 2023 were the Siemens Innovance D-dimer (42%), the IL HemosIL D-dimer HS 500 (20%), and the Diagnostica Stago (Stago) Liatest D-dimer Plus (10%)—all these are automated, quantitative, latex immunoassays expressed in fibrinogen equivalent units (FEU). The highest interlaboratory variability was observed around the typical VTE exclusion threshold of 0.5 mg/L FEU. Lower interlaboratory variability was observed at values above 0.8 mg/L FEU. Our study provides recent, international performance data on currently used D-dimer assays and describes the significant variability between assays and across D-dimer concentrations. We demonstrate that assays are not interchangeable and that using them interchangeably has the potential to result in clinically important errors. There is an urgent need to educate users about these issues and to work towards harmonizing D-dimer units and reporting.

Keywords

D-dimer - diagnosis - assay variability - thrombosis - quality

Authors' Contributions

C.E., M.J.H., and R.S. contributed to the entire manuscript development. M.J.H. conducted the data analysis. P.M. provided the laboratory data and contributed to the writing. Z.L. contributed to the manuscript optimization.

^* These authors contributed equally to this article.

Publikationsverlauf

Artikel online veröffentlicht:
17. Oktober 2024

• References

• 1 Linkins LA, Takach Lapner S. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol 2017; 39 (Suppl. 01) 98-103
• 2 Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. Am J Hematol 2019; 94 (07) 833-839
• 3 Kearon C, Spencer FA, O'Keeffe D. et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162 (01) 27-34
• 4 Righini M, Van Es J, Den Exter PL. et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014; 311 (11) 1117-1124
• 5 Takach Lapner S, Julian JA, Linkins LA, Bates S, Kearon C. Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism. Thromb Haemost 2017; 117 (10) 1937-1943
• 6 Rodger MA, Le Gal G, Anderson DR. et al; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356: j1065
• 7 Khan F, Rahman A, Carrier M. et al; MARVELOUS Collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: l4363
• 8 Verhovsek M, Douketis JD, Yi Q. et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149 (07) 481-490 , W94
• 9 Bakhtiari K, Meijers JCM, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32 (12) 2416-2421
• 10 Al-Samkari H, Karp Leaf RS, Dzik WH. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136 (04) 489-500
• 11 Dempfle CE. D-dimer assays: the current status and new assay technologies. Thromb Res 2006; 118 (05) 569-571
• 12 Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost 2006; 95 (03) 567-572
• 13 Longstaff C, Adcock D, Olson JD. et al. Harmonisation of D-dimer - a call for action. Thromb Res 2016; 137: 219-220
• 14 Thachil J, Longstaff C, Favaloro EJ, Lippi G, Urano T, Kim PY. SSC Subcommittee on Fibrinolysis of the International Society on Thrombosis and Haemostasis. The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. J Thromb Haemost 2020; 18 (09) 2408-2411
• 15 Ecat Foundation. ECAT website. [e-mail]. Accessed August 25, 2024 at: https://www.ecat.nl
• 16 Jennings I, Kitchen DP, Woods TAL, Kitchen S, Preston FE, Walker ID. Stability of coagulation proteins in lyophilized plasma. Int J Lab Hematol 2015; 37 (04) 495-502
• 17 International Organization for Standardization. ISO 13528:2015. Statistical methods for use in proficiency testing by inter-laboratory comparisons.
• 18 Di Nisio M, Squizzato A, Rutjes AWS, Büller HR, Zwinderman AH, Bossuyt PMM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 2007; 5 (02) 296-304
• 19 Carrier M, Righini M, Djurabi RK. et al. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. Thromb Haemost 2009; 101 (05) 886-892
• 20 Michiels JJ, Gadisseur A, van der Planken M. et al. Different accuracies of rapid enzyme-linked immunosorbent, turbidimetric, and agglutination D-dimer assays for thrombosis exclusion: impact on diagnostic work-ups of outpatients with suspected deep vein thrombosis and pulmonary embolism. Semin Thromb Hemost 2006; 32 (07) 678-693
• 21 de Moerloose P, Palareti G, Aguilar C, Legnani C, Reber G, Peetz D. A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. Thromb Haemost 2008; 100 (03) 505-512
• 22 Salvagno GL, Lippi G, Montagnana M. et al. Performance of the automated and rapid HemosIL D-Dimer HS on the ACL TOP analyzer. Blood Coagul Fibrinolysis 2008; 19 (08) 817-821
• 23 Hamer HM, Stroobants AK, Bavalia R. et al. Diagnostic accuracy of four different D-dimer assays: a post-hoc analysis of the YEARS study. Thromb Res 2021; 201: 18-22
• 24 Rodger MA, Le Gal G, Langlois NJ. et al; REVERSE II investigators. “HERDOO2” clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any d-Dimer?. Thromb Res 2018; 169 (July): 82-86
• 25 Favaloro EJ, Dean E, Arunachalam S. Variable performance of D-Dimer testing: the Australasian/Asia-Pacific experience. Semin Thromb Hemost 2024; (e-pub ahead of print).
• 26 Ingber S, Selby R, Lee J, Geerts W, Brnjac E. Combination pretest probability assessment and D-dimer did not reduce outpatient imaging for venous thromboembolism in a tertiary care hospital emergency department. CJEM 2014; 16 (01) 53-62
• 27 Favaloro EJ, Dean E. Variability in D-dimer reporting revisited. Pathology 2021; 53 (04) 538-540
• 28 Meijer P, Haverkate F, De Maat MP. Performance of quantitative D-dimer assays in the ECAT external quality assessment programme. Fibrinolysis Proteol 2000; 14 (Suppl. 01) 83
• 29 Tripodi A, Chantarangkul V. Performance of quantitative D-dimer methods: results of the Italian external quality assessment scheme. J Thromb Haemost 2007; 5 (01) 184-185
• 30 Spannagl M, Haverkate F, Reinauer H, Meijer P. The performance of quantitative D-dimer assays in laboratory routine. Blood Coagul Fibrinolysis 2005; 16 (06) 439-443
• 31 Olson JD, Cunningham MT, Higgins RA, Eby CS, Brandt JT. D-dimer: simple test, tough problems. Arch Pathol Lab Med 2013; 137 (08) 1030-1038
• 32 Sholzberg M, Tang GH, Rahhal H. et al; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400
• 33 Lopes RD, de Barros E Silva PGM, Furtado RHM. et al; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397 (10291): 2253-2263
• 34 Spyropoulos AC, Goldin M, Giannis D. et al; HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
• 35 Goligher EC, Bradbury CA, McVerry BJ. et al; REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med 2021; 385 (09) 777-789
• 36 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019 (COVID- 19): a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
• 37 García de Guadiana-Romualdo L, Morell-García D, Favaloro EJ. et al. Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study). J Thromb Thrombolysis 2022; 53 (01) 103-112